Definium Therapeutics (MMQ0) Income Statement
Definium Therapeutics Income Statement
Last quarter (Q2 2026), Definium Therapeutics's total revenue was $0.00. In Q2, Definium Therapeutics's net income was $-158.99M. See Definium Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ -527.00K | $ -3.16M | $ 0.00 | $ 0.00 | |
| $ 166.31M | $ 103.39M | $ 90.70M | $ 66.33M | $ 93.85M | |
| Depreciation and Amortization | $ 0.00 | $ 527.00K | $ 3.16M | $ 3.18M | $ 2.62M |
| $ -178.31M | $ -105.87M | $ -92.57M | $ -52.12M | $ -91.22M | |
| $ -166.31M | $ -103.92M | $ -93.87M | $ -66.33M | $ -93.85M | |
| $ -17.48M | $ -4.76M | $ -1.87M | $ 9.54M | $ -339.00K | |
| $ -183.79M | $ -108.68M | $ -95.73M | $ -56.80M | $ -94.19M | |
| $ -183.79M | $ -108.68M | $ -95.73M | $ -56.80M | $ -93.04M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.06 | $ -1.54 | $ -2.44 | $ -1.53 | $ -3.40 |
| Diluted EPS | $ -2.06 | $ -0.15 | $ -2.44 | $ -1.53 | $ -3.40 |
| Weighted Average Shares Outstanding | 89.33M | 70.46M | 39.16M | 30.86M | 27.38M |
| Weighted Average Shares Outstanding (Diluted) | 89.33M | 704.61M | 39.16M | 30.86M | 27.38M |
Currency in USD
